Zhao Yong, Huang Zhihua, Qi Meirigeng, Lazzarini Ping, Mazzone Theodore
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, 1819 W. Polk Street, Chicago, IL 60612, USA.
Immunol Lett. 2007 Jan 15;108(1):78-87. doi: 10.1016/j.imlet.2006.10.007. Epub 2006 Nov 27.
Previous work identified a novel type of stem cell from human umbilical cord blood, designated cord blood-stem cells (CB-SC). To further evaluate their immune characteristics, we cocultured CB-SC with allogeneic peripheral blood lymphocytes in the presence of phytohaemagglutinin (PHA) or interleukin-2 (IL-2). Results showed that CB-SC could significantly inhibit lymphocyte proliferation and reduce tyrosine phosphorylation of STAT5 in both PHA- and IL-2-stimulated lymphocytes, along with the regulation on the phenotypes of CD4+ and CD8+ T cells. Additionally, CB-SC also suppressed the proliferation of IL-2-stimulated CD4+CD25+ regulatory T cells. Mechanism studies revealed that programmed death receptor-1 ligand 1 (PD-L1) expressed on CB-SC membrane, together with a soluble factor nitric oxide (NO) released by PHA-stimulated CB-SC, not prostaglandin E2 (PGE2) and transforming growth factor-beta1 (TGF-beta1), mainly contributed to the T cell suppression induced by CB-SC, as demonstrated by blocking experiments with a nitric oxide synthase inhibitor (Nomega-nitro-l-arginine, l-NNA) and a neutralizing antibody to PD-L1. Our findings may advance our understanding of the immunobiology of stem cells and facilitate the therapeutic application of cord blood stem cells.
先前的研究从人脐带血中鉴定出一种新型干细胞,命名为脐带血干细胞(CB-SC)。为了进一步评估其免疫特性,我们在植物血凝素(PHA)或白细胞介素-2(IL-2)存在的情况下,将CB-SC与异基因外周血淋巴细胞共培养。结果显示,CB-SC能显著抑制淋巴细胞增殖,并降低PHA和IL-2刺激的淋巴细胞中STAT5的酪氨酸磷酸化,同时还能调节CD4+和CD8+ T细胞的表型。此外,CB-SC还能抑制IL-2刺激的CD4+CD25+调节性T细胞的增殖。机制研究表明,CB-SC膜上表达的程序性死亡受体-1配体1(PD-L1),以及PHA刺激的CB-SC释放的可溶性因子一氧化氮(NO),而非前列腺素E2(PGE2)和转化生长因子-β1(TGF-β1),是CB-SC诱导T细胞抑制的主要原因,一氧化氮合酶抑制剂(Nω-硝基-L-精氨酸,L-NNA)和抗PD-L1中和抗体的阻断实验证明了这一点。我们的研究结果可能会增进我们对干细胞免疫生物学的理解,并促进脐带血干细胞的治疗应用。